Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease
Stefan James(Uppsala University Hospital), David Erlinge(Lund University), Patricia Brown(Eli Lilly (United States)), Scott S. Sundseth, Paul A. Gurbel(Sinai Hospital), Kenneth J. Winters(Eli Lilly (United States)), Brian A. Moser(Eli Lilly (United States)), Christoph Varenhorst, Henrik Wagner(Örebro University Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Joseph R. Walker(Daiichi Sankyo (United States)), David S. Small(Eli Lilly (United States)), Udaya S. Tantry(Sinai Hospital), Suman Duvvuru(Eli Lilly (United States))
Cited by 21
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617